Title: Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis
Authors: Ruperto, Nicolino ×
Brunner, Hermine I
Quartier, Pierre
Constantin, Tamás
Wulffraat, Nico
Horneff, Gerd
Brik, Riva
McCann, Liza
Kasapcopur, Ozgur
Rutkowska-Sak, Lidia
Schneider, Rayfel
Berkun, Yackov
Calvo, Inmaculada
Erguven, Muferet
Goffin, Laurence
Hofer, Michael
Kallinich, Tilmann
Oliveira, Sheila K
Uziel, Yosef
Viola, Stefania
Nistala, Kiran
Wouters, Carine
Cimaz, Rolando
Ferrandiz, Manuel A
Flato, Berit
Gamir, Maria Luz
Kone-Paut, Isabelle
Grom, Alexei
Magnusson, Bo
Ozen, Seza
Sztajnbok, Flavio
Lheritier, Karine
Abrams, Ken
Kim, Dennis
Martini, Alberto
Lovell, Daniel J
Issue Date: Dec-2012
Series Title: New England Journal of Medicine vol:367 issue:25 pages:2396-2406
Article number: 10.1056/NEJMoa1205099
Abstract: Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Pediatric Immunology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis.pdf Published 527KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science